Monograph Title | Section | Source Publication | Page Number | Errata Post Date | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication Sort ascending | Description |
---|---|---|---|---|---|---|---|---|
ATRACURIUM BESYLATE INJECTION | IMPURITIES/Organic Impurities/Acceptance criteria/Table 2 | Second Supplement to USP35–NF30 | 5909 | 29-Mar-2013 | 1-Apr-2013 | USP37–NF32 | USP37–NF32 | Footnote b: Change cis isomer of the hydroxy compound. to: trans isomer of the hydroxy compound. AND Footnote c: Change trans isomer of the hydroxy compound. to: cis isomer of the hydroxy compound. AND Footnote d: Change cis… Read More |
HYMETELLOSE | IMPURITIES/Chloride and Sulfate, Chloride <221> | USP36–NF31 | 2044 | 29-Mar-2013 | 1-Apr-2013 | USP37–NF32 | USP37–NF32 | Change the subsection title Standard solution to: Control solution AND Line 4 of Analysis: Change Standard solution to: Control solution AND Line 2 of Acceptance criteria: Change Standard solution to: … Read More |
OXYCODONE AND ACETAMINOPHEN TABLETS | IDENTIFICATION/A. Thin-Layer Chromatography | USP36–NF31 | 4645 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 2 of Sample solution: Change in a mixture of methanol and water (4:1). to: in a 5-mL mixture of methanol and water (4:1). |
METHENAMINE ORAL SOLUTION | ASSAY/Procedure | USP36–NF31 | 4288 | 29-Mar-2013 | 1-Apr-2013 | USP37–NF32 | USP37–NF32 | Line 10 of Analysis: Change BS = absorbance of the Sample blank to: BS = absorbance of the Standard blank |
POTASSIUM CHLORIDE, POTASSIUM BICARBONATE, AND POTASSIUM CITRATE EFFERVESCENT TABLETS FOR ORAL SOLUTION | Assay for potassium | USP36–NF31 | 4843 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 2: Change Potassium stock solution and Standard preparations— to: Standard stock solution and Standard solutions— AND Line 1 of Procedure: Change for Procedure in the Assay under Potassium Chloride Oral Solution. … Read More |
AMITRIPTYLINE HYDROCHLORIDE TABLETS | IDENTIFICATION/A. | USP36–NF31 | 2464 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 2: Change Sample solution: Nominally 0.01 mg/mL of amitriptyline hydrochloride in methanol from a suitable amount of finely powdered Tablets. Filter a portion of the solution, and use the filtrate for analysis. to: Sample stock solution: Nominally 0.1 mg/mL of… Read More |
LEVETIRACETAM | ADDITIONAL REQUIREMENTS | USP35–NF30 | 3659 | 29-Mar-2013 | 1-Apr-2013 | USP37–NF32 | USP37–NF32 | Line 9 of USP Reference Standards <11>: Change
C8H14ClNO3 207.65 to: C8H15ClN2O2 206.67 |
INOSITOL | SPECIFIC TESTS/Conductivity | USP36–NF31 | 2049 | 29-Mar-2013 | 1-Apr-2013 | USP37–NF32 | USP37–NF32 | Line 1 of Sample solution: Change Transfer 10.0 g of Inositol, weighed and calculated on the dried basis, to a 50-mL volumetric flask, and dissolve in and dilute with water (previously boiled and cooled to room temperature) to volume. to: 0.2 g/mL of Inositol in water (previously… Read More |
OXYCODONE TEREPHTHALATE | ASSAY/Procedure | USP36–NF31 | 4648 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 7 of Analysis: Change RU = internal standard ratio (peak response of oxycodone/peak response of ethylparaben) from the Standard solution RS = internal standard ratio (peak response of oxycodone/peak response of ethylparaben) from the … Read More |
CALCIUM SULFATE | SPECIFIC TESTS/Loss on Drying <731> | USP35–NF30 | 1724 | 29-Mar-2013 | 1-Apr-2013 | USP37–NF32 | USP37–NF32 | Line 1 of Acceptance criteria: Change NMT 1.5% for the anhydrous form and NMT 19.0%–23.0% for the dihydrate to: NMT 1.5% for the anhydrous form and 19.0%–23.0% for the dihydrate |
SELEGILINE HYDROCHLORIDE TABLETS | Dissolution <711> | USP36–NF31 | 5120 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 3 of Chromatographic system: Change Chromatograph the Standard solution, and record the peak responses. to: The flow rate is 1.0 mL/min. Chromatograph the Standard solution, and record the peak responses. |
FOSPHENYTOIN SODIUM | USP Reference standards <11> | USP36–NF31 | 3679 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 6: Change C14H15NO2 to: C14H13NO2 |
VANCOMYCIN INJECTION | SPECIFIC TESTS/Composition of Vancomycin | USP35–NF30 | 5003 | 29-Mar-2013 | 1-Apr-2013 | USP37–NF32 | USP37–NF32 | Line 16 of Analysis: Change D = dilution factor, Sample stock solution to Sample solution, 25 to: D = dilution factor, Sample stock solution to Sample solution AND Line 29 of Analysis: Change D = dilution factor, … Read More |
HYDROGENATED POLYDECENE | ASSAY/Content of Decene Oligomer | USP36–NF31 | 2133 | 29-Mar-2013 | 1-Apr-2013 | USP37–NF32 | USP37–NF32 | Line 3 of System suitability: Change [Note—The retention time for squalene is about 18 min; the relative retention times for tetradecane, hexadecane, and squalene are about 0.5, 0.6, and 1.0, respectively.] to: [Note—The retention time for squalane is about 18 min; the relative… Read More |
PENTAZOCINE INJECTION | Chemical Information | USP36–NF31 | 4734 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 1: Remove all chemical information. |
IFOSFAMIDE | Chloroform-insoluble phosphorus | USP35–NF30 | 3477 | 29-Mar-2013 | 1-Apr-2013 | USP37–NF32 | USP37–NF32 | Line 18 of Test preparation: Change ammonium hydroxide solution. to: ammonium hydroxide. |
TACROLIMUS CAPSULES | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP36–NF31 | 5257 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 11 of USP Tacrolimus System Suitability Mixture RS: Change
and tacrolimus 8-propyl analog (3S,4R,5S,8S,9E,12S,14S,15R,16S,18R,19R,26aS)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,… Read More |
FOSPHENYTOIN SODIUM INJECTION | USP Reference standards <11> | USP36–NF31 | 3680 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 6: Change C14H15NO2 to: C14H13NO2 |
VINORELBINE INJECTION | Related compounds | USP35–NF30 | 5028 | 29-Mar-2013 | 1-Apr-2013 | USP37–NF32 | USP37–NF32 | Delete the subsection Standard solution and Diluted standard solution. Replace with: Standard solution—Dissolve an accurately weighed quantity of USP Vinorelbine Tartrate RS in Mobile phase to obtain a solution having a known concentration of about 1.4 mg per mL.… Read More |
POLYVINYL ACETATE PHTHALATE | IMPURITIES/Free Phthalic Acid | USP36–NF31 | 2168 | 29-Mar-2013 | 1-Apr-2013 | USP37–NF32 | USP37–NF32 | Line 1 of Sample solution: Change 6 mg/mL of polyvinyl acetate to: 6 mg/mL of polyvinyl acetate phthalate |
POTASSIUM BICARBONATE EFFERVESCENT TABLETS FOR ORAL SOLUTION | Assay | USP36–NF31 | 4833 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 2: Change Potassium stock solution and Standard preparations— to: Standard stock solution and Standard solutions— AND Line 1 of Procedure: Change for Procedure in the Assay under Potassium Chloride Oral Solution. to… Read More |
METHOTREXATE | IMPURITIES/Organic Impurities/Procedure 1: Related Compounds | USP35–NF30 | 3855 | 29-Mar-2013 | 1-Apr-2013 | USP37–NF32 | USP37–NF32 | Footnote b of Impurity Table 1: Change (S)-2-{4-[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methylamino]-N-methylbenzamido}pentanedioic acid. to: (S)-2-(4-{[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methyl](methyl)amino}benzamido)pentanedioic acid. |
THIMEROSAL TOPICAL AEROSOL | SPECIFIC TESTS/Alcohol Determination, Method II <611> | USP36–NF31 | 5369 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 4 of Analysis: Change Determine the alcohol content of the sample thus prepared by the Gas–Liquid Chromatographic Method (see Method II in Alcohol Determination <611>, using methyl ethyl ketone as the internal standard in place of acetone. to: … Read More |
FOSPHENYTOIN SODIUM INJECTION | Assay | USP36–NF31 | 3680 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 1 of Assay preparation: Change Transfer an accurately measured volume of the Injection, equivalent to about 300 mg of fosphenytoin, to: Transfer an accurately measured volume of the Injection, equivalent to about 300 mg of fosphenytoin sodium, |
VINORELBINE INJECTION | Assay | USP35–NF30 | 5028 | 29-Mar-2013 | 1-Apr-2013 | USP37–NF32 | USP37–NF32 | Line 1: Change Phosphate buffer, Mobile phase, and System suitability solution—Proceed as directed in the Assay under Vinorelbine Tartrate. to: Phosphate buffer—Dissolve 6.9 g of monobasic sodium phosphate in 900 mL of water. Adjust with phosphoric acid… Read More |
PROPYLENE GLYCOL MONOLAURATE | IMPURITIES/Limit of Propylene Glycol | USP36–NF31 | 2180 | 29-Mar-2013 | 1-Apr-2013 | USP37–NF32 | USP37–NF32 | Line 8 of Analysis: Change Calculate the percentage of free propylene glycol in the portion of Propylene Glycol Monocaprylate taken: to: Calculate the percentage of free propylene glycol in the portion of Propylene Glycol Monolaurate taken: |
POTASSIUM BICARBONATE AND POTASSIUM CHLORIDE FOR EFFERVESCENT ORAL SOLUTION | Assay for potassium | USP36–NF31 | 4834 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 2: Change Potassium stock solution and Standard preparations— to: Standard stock solution and Standard solutions— AND Line 1 of Procedure: Change for Procedure in the Assay under Potassium Chloride Oral Solution. to… Read More |
ISOTRETINOIN CAPSULES | PERFORMANCE TESTS/Dissolution <711>/Test 4 | Revision Bulletin (Official October 01, 2012) | Online | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 2 of Medium: Change 4.5% (v/v) of Milloxid L (lauryl dimethyl amine oxide) to: 4.5% (v/v) of lauryl dimethyl amine oxide |
TROLAMINE SALICYLATE | Assay | USP36–NF31 | 5499 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 3 of Chromatographic system: Change L1 to: L7 |
MINOCYCLINE HYDROCHLORIDE CAPSULES | Assay | USP36–NF31 | 4375 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 2: Change Mobile phase, Standard preparation, Resolution solution, and Chromatographic system—Proceed as directed in the Assay under Minocycline Hydrochloride. to: Mobile phase—Prepare a mixture of 0.2 M ammonium oxalate, 0.01 M edetate… Read More |
ZINC SULFATE TABLETS | Identification/B. Zinc | USP35–NF30 | 5077 | 29-Mar-2013 | 1-Apr-2013 | USP37–NF32 | USP37–NF32 | Line 1 of Sodium hydroxide solution: Change 42 mg/mL of sodium hydroxide to: 420 mg/mL of sodium hydroxide |
BENZTROPINE MESYLATE | CHEMICAL INFORMATION | USP36–NF31 | 2628 | 29-Mar-2013 | 1-Apr-2013 | USP37–NF32 | USP37–NF32 | Line 2: Change 8-Azabicyclo[3.2.1]octane, 3-(diphenylmethoxy)-, endo-, methanesulfonate; to: 8-Azabicyclo[3.2.1]octane, 3-(diphenylmethoxy)-N-methyl-, endo-, methanesulfonate; |
POTASSIUM BICARBONATE AND POTASSIUM CHLORIDE EFFERVESCENT TABLETS FOR ORAL SOLUTION | Assay for potassium | USP36–NF31 | 4834 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 2: Change Potassium stock solution and Standard preparations— to: Standard stock solution and Standard solutions— AND Line 1 of Procedure: Change for Procedure in the Assay under Potassium Chloride Oral Solution. to… Read More |
<228> ETHYLENE OXIDE AND DIOXANE | Method II | USP36–NF31 | 148 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 31 of Analysis: Change rS = ethylene oxide peak responses from Standard solution B to: rS = dioxane peak responses from Standard solution B |
AZITHROMYCIN | IMPURITIES/Organic Impurities/Procedure 2 | USP35–NF30 | 2279 | 29-Mar-2013 | 1-Apr-2013 | USP37–NF32 | USP37–NF32 | Line 15 of Analysis: Change CS = concentration of USP Azithromycin RS in the Standard solution (µg/mL) to: CS = concentration of USP Azithromycin RS in the Standard solution (mg/mL) AND Add after CU: P = potency of USP… Read More |
VERAPAMIL HYDROCHLORIDE ORAL SOLUTION | Assay | USP36–NF31 | 5558 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 3 of Sodium acetate solution: Change 0.01 M to: 0.01 N AND Line 6 of Assay preparation: Change 10-mL to: 100-mL |
REAGENTS, INDICATORS AND SOLUTIONS | Solutions/Test Solutions/3. Solutions Prepared Fresh | USP40–NF35 | 2419 | 29-Dec-2017 | 1-Jan-2018 | USP42–NF37 | Second Supplement to USP41–NF36 | Line 2 of 0.06 M Phosphoric Acid TS: Change volumetric flask to: 1000-mL volumetric flask |
HYDROCHLOROTHIAZIDE CAPSULES | PERFORMANCE TESTS/Dissolution/Test 2 | USP41–NF36 | 2049 | 31-Aug-2018 | 1-Sep-2018 | USP43–NF38 | Second Supplement to USP41–NF36 | Line 1 of Empty capsules solution: Change Place 10 Capsules into to: Place 10 empty capsules into |
ESZOPICLONE TABLETS | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | Revision Bulletin (Official August 01, 2017) | Online | 26-Jan-2018 | 1-Feb-2018 | USP42–NF37 | Second Supplement to USP41–NF36 | Line 2 of USP Eszopiclone Related Compound A RS: Change 6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-yl 4-methylpiperazine-1-carboxylate 4-oxide. C17H17ClN6O4 404.81 to: [Note—This… Read More |
<1601> PRODUCTS FOR NEBULIZATION—CHARACTERIZATION TESTS | AERODYNAMIC ASSESSMENT OF NEBULIZED AEROSOLS | USP41–NF36 | 7874 | 25-May-2018 | 1-Jun-2018 | USP42–NF37 | Second Supplement to USP41–NF36 | Line 1 of paragraph 3: Change general information chapter Aerosols, Nasal Sprays, Metered-Dose Inhalers, and Dry Powder Inhalers <601>), to: general chapter Inhalation and Nasal Drug Products: Aerosols, Sprays, and Powders—… Read More |
ACETAMINOPHEN ORAL SUSPENSION | IMPURITIES/Organic Impurities | Revision Bulletin (Official August 01, 2018) | Online | 28-Sep-2018 | 1-Oct-2018 | USP43–NF38 | Second Supplement to USP41–NF36 | This erratum applies to the new USP-NF ONLINE platform only. Change Solution B: 0.2% trifluoroacetic acid in water to: Solution B: 0.2% trifluoroacetic acid in acetonitrile |
DOBUTAMINE IN DEXTROSE INJECTION | Identification | USP40–NF35 | 3843 | 26-Jan-2018 | 1-Feb-2018 | USP42–NF37 | Second Supplement to USP41–NF36 | Line 1 of B: Change It meets the requirements for the Identification test under Dextrose. to: Add a few drops of a solution (1 in 20) to 5 mL of hot alkaline cupric tartrate TS. A copious red precipitate of cuprous oxide is formed. |
METHADONE HYDROCHLORIDE INJECTION | ASSAY/Procedure | USP41–NF36 | 2628 | 28-Sep-2018 | 1-Oct-2018 | USP43–NF38 | Second Supplement to USP41–NF36 | In the Analysis: Change Result = (RU/RS) × W × 100 to: Result = (RU/RS) × W |
DONEPEZIL HYDROCHLORIDE | IMPURITIES/Organic Impurities, Procedure 2 | USP40–NF35 | 3859 | 17-Nov-2017 | 1-Dec-2017 | USP42–NF37 | Second Supplement to USP41–NF36 | Footnote b of Table 3: Change (E)-4-[(5,6-Dimethoxy-1-oxo-1H-inden-2-yl)methyl]pyridine 1-oxide. to: (E)-4-[(5,6-Dimethoxy-1-oxo-1,3-dihydro-2H-inden-2-ylidene)methyl]pyridine 1-oxide. |
<601> INHALATION AND NASAL DRUG PRODUCTS: AEROSOLS, SPRAYS, AND POWDERS—PERFORMANCE QUALITY TESTS | C. AERODYNAMIC SIZE DISTRIBUTION—INHALATION AEROSOLS, SPRAYS, AND POWDERS | USP41–NF36 | 6327 | 23-Feb-2018 | 1-Mar-2018 | USP42–NF37 | Second Supplement to USP41–NF36 | Figure 6: Change Boquilla del Inhalador to: Inhaler Mouthpiece AND Change Tubo de Admisión to: Induction Port AND Change Cono de Ingreso to: Entrance Cone |
<198> NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY IDENTITY TESTING OF BACTERIAL POLYSACCHARIDES USED IN VACCINE MANUFACTURE | 2. PROCEDURE | First Supplement to USP41–NF36 | 8633 | 29-Jun-2018 | 1-Jul-2018 | USP42–NF37 | Second Supplement to USP41–NF36 | Line 3 of 2.1 Equipment Requirements/Processing Parameters: Change adsorption to: absorption |
STERILE WATER FOR IRRIGATION | ADDITIONAL REQUIREMENTS | USP41–NF36 | 4347 | 26-Oct-2018 | 1-Nov-2018 | USP43–NF38 | Second Supplement to USP41–NF36 | Delete • USP Reference Standards <11> USP 1,4-Benzoquinone RS |
RACEPINEPHRINE | USP Reference standards <11> | USP41–NF36 | 3564 | 27-Jul-2018 | 1-Aug-2018 | USP43–NF38 | Second Supplement to USP41–NF36 | Add USP Epinephrine Bitartrate RS |
POWDERED ECHINACEA PALLIDA EXTRACT | IDENTIFICATION | USP40–NF35 | 6935 | 26-Jan-2018 | 1-Feb-2018 | USP42–NF37 | Second Supplement to USP41–NF36 | Line 5 of A. Thin-Layer Chromatography/Presence of echinacoside and absence of dicaffeoylquinic acid/System suitability: Change Standard solution B shows two major blue bands at about the middle of the chromatogram due to caftaric acid (lower RF… Read More |
PEMETREXED FOR INJECTION | ASSAY/Procedure/Analysis | First Supplement to USP41–NF36 | Online | 27-Apr-2018 | 1-May-2018 | USP42–NF37 | Second Supplement to USP41–NF36 | Line 8 of the variable definition list: Change Mr2 = molecular weight of pemetrexed disodium (anhydrous), 473.37 to: Mr2 = molecular weight of pemetrexed disodium (anhydrous), 471.38 |